Entia Biosciences
OTCMKTS:ERGOEntia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.
![Genius Group Genius Group logo](https://www.marketbeat.com/logos/genius-group-limited-logo.png?v=20230202140446)
Genius Group
NYSEAMERICAN:GNSGenius Group Limited, through its subsidiaries, provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company operates through two segments, Education and Campus. It develops comprehensive entrepreneurial education curriculum with a full suite of tools for student learning and faculty earning. The company also owns entrepreneur resorts in Bali and South Africa, which run entrepreneur retreats and workshops; and Genius Café, an entrepreneur beach club in Bali, as well as Genius Central, an entrepreneur co-working hub in Singapore. In addition, it offers home childcare and investment education services; operates entrepreneur education campus that provides a range of programs from pre-primary through primary school, secondary school, and vocational college; and provides career-focused on-campus and online programs at the master's, bachelor's and associate degree level, as well as certificate and continuing education programs. The company operates in Europe/the Middle East/Africa, the Asia/Pacific, and North America/South America. Genius Group Limited was founded in 2002 and is headquartered in Singapore.
PureTech Health
NASDAQ:PRTCPureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.